Document is current
Any future updates will be listed below
-
Authors
Hultman, Johanna https://orcid.org/0009-0000-8066-228X
Morad, Vivian https://orcid.org/0000-0001-9665-4532
Tanner, Eliane
Kenney, Tristan M. G. https://orcid.org/0000-0001-8242-4349
Pietras, Zuzanna https://orcid.org/0000-0002-4501-7311
Khare, Lalit Pramod
Derbyshire, Dean
Resetca, Diana
Arrowsmith, Cheryl H.
Aili, Daniel https://orcid.org/0000-0002-7001-9415
Ekström, Simon https://orcid.org/0000-0002-7694-285X
Penn, Linda Z. https://orcid.org/0000-0001-8133-5459
Wallner, Björn https://orcid.org/0000-0002-3772-8279
Ahlner, Alexandra https://orcid.org/0000-0001-7004-8251
Sunnerhagen, Maria https://orcid.org/0000-0002-0492-5890
- License Information
-
More Information
Article History
Received: 20 March 2025
Accepted: 9 February 2026
First Online: 24 February 2026
Competing interests
: MS is a co-founder and shareholder of MyCural Therapeutics, a company which develops small-molecules targeting the MYC-MAX interaction. No other author declare any competing interests.
